FDA Warning Letter Explorer
Drugs · Letter issue date: Oct 27, 2025

IBSPOT.com Inc.

2 extracted findings · 2 model-assigned issue types

FDA source excerpt, selected passage

FDA confirmed through laboratory analyses that “Taoscare Motion Sickness Patch” and “Navabelle Motion Sickness Patches” purchased on www.ibspot.com contained the ingredients diphenhydramine, diphenhydramine N-oxide, and diclofenac, which are not listed on the product labels.

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Labeling, claims & marketing

Products contained undeclared active ingredients, making them misbranded under section 502(a).

Supporting FDA text
Source excerpt · automated text-match check

FDA confirmed through laboratory analyses that “Taoscare Motion Sickness Patch” and “Navabelle Motion Sickness Patches” purchased on www.ibspot.com contained the ingredients diphenhydramine, diphenhydramine N-oxide, and diclofenac, which are not listed on the product labels.

Registration, listing & premarket

Products are unapproved new drugs marketed without FDA-approved applications, violating FD&C Act sections 301(d) and 505(a).

Supporting FDA text
Source excerpt · automated text-match check

No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs and the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

Findings extracted from the letter

Selected FDA passages, not the complete letter.

01
FDA confirmed through laboratory analyses that “Taoscare Motion Sickness Patch” and “Navabelle Motion Sickness Patches” purchased on www.ibspot.com contained the ingredients diphenhydramine, diphenhydramine N-oxide, and diclofenac, which are not listed on the product labels.

Source passage selected by the model

02
No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs and the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

Source passage selected by the model

What FDA requested

Model-assisted summary. Consult the letter for complete requests and conditions.

  • Notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps taken to correct any violations, including an explanation of each step being taken to prevent recurrence and copies of related documentation.
  • If the products are believed not to be in violation, include reasoning and supporting information.
  • If corrective action cannot be completed within fifteen working days, state the reason for the delay and the time within which correction will be completed.

Sections and clauses cited

As cited in this historical letter, not a statement of current regulatory requirements.

Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.